Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40969 ENTRADA THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: | Title of Each Class ...

– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial ...

– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada The ...

Biotech investors sometimes overlook companies solving fundamental drug development problems. Entrada Therapeutics (NASDAQ: TRDA ) operates in one such space, solving the enduring problem of intracellular drug delivery. Although much of the sector is under capital constraints andI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My ...

– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ...

Exhibit 99.1 2025 J.P. Morgan Healthcare Conference NASDAQ: TRDA Disclaimer This presentation has been prepared by Entrada Therapeutics. Inc. (the "Corpany") and shall not constitute an offer to sell or a solicitation ol or inducement to engage in investment activity nor shall there be any sale of securities in any juisdiction in which such offer, solicitation or sa or qualification of such securities under the securities law of any such jurisdiction. The Company has filed a shelf registration statement (in ...

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will be available ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Clinical Trials and Product Development - The company reported positive preliminary data from the Phase 1 clinical trial of ENTR-601-44, with muscle concentration detected in all six subjects in the 6 mg/kg dose cohort (mean of 53.8 ng/g) and mean target engagement as measured by exon skipping at 0.44%[104][108]. - The Phase 1 clinical trial included 32 healthy male volunteers across four cohorts, with doses of 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, and 6 mg/kg administered[106]. - The company plans to submit regulatory applications in Q4 2024 for ENTR-601-44 and ENTR-601-45, and in 2025 for ENTR-601-50, all targeting Duchenne muscular dystrophy[109][110]. Financial Performance and Revenue - Collaboration revenue for the three months ended September 30, 2024, was $19.6 million, a decrease of $24.2 million from $43.7 million in the same period of 2023[136]. - For the nine months ended September 30, 2024, collaboration revenue was $173.4 million, an increase of $86.2 million from $87.2 million in the same period of 2023[145]. - The net loss for the three months ended September 30, 2024, was $14.0 million, compared to a net income of $35.5 million in the same period of 2023, reflecting a change of $49.5 million[136]. - The company does not expect to generate revenue from product sales until successful completion of clinical development and regulatory approval[120]. Expenses and Cash Flow - Research and development expenses primarily consist of costs related to personnel, third-party agreements, and manufacturing processes, with a focus on neuromuscular program development[121][124]. - Research and development expenses increased to $31.3 million for the three months ended September 30, 2024, up by $9.1 million from $22.2 million in the same period of 2023[139]. - Total operating expenses for the nine months ended September 30, 2024, were $120.5 million, up by $25.3 million from $95.2 million in the same period of 2023[144]. - The company anticipates that research and development expenses will continue to increase as it advances its therapeutic candidates through clinical trials[140]. - Net cash used in operating activities was $10.0 million for the nine months ended September 30, 2024, compared to net cash provided of $143.8 million in the same period of 2023[154][157]. - Net cash used in investing activities was $81.2 million for the nine months ended September 30, 2024, compared to $157.4 million in the same period of 2023[158][159]. - Net cash provided by financing activities was $101.6 million for the nine months ended September 30, 2024, significantly up from $20.3 million in the same period of 2023[160][161]. Funding and Financial Position - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $449.3 million, expected to fund operations into 2027[119]. - The company has raised over $850.0 million in gross proceeds from equity sales and the Vertex Agreement since inception[113]. - The accumulated deficit as of September 30, 2024, was $130.5 million, with expectations of continued operating losses and negative cash flows[114]. - The company expects to incur significant operating losses and negative cash flows for the foreseeable future as it advances its EEV Platform and therapeutic candidates[162]. - The company anticipates that its cash resources will be sufficient to fund operations into 2027 based on current operating plans[162]. Regulatory and Reporting Status - The company qualifies as an Emerging Growth Company (EGC) and intends to take advantage of exemptions under the JOBS Act, including reduced reporting requirements[171]. - The company will remain an EGC until the earliest of five years post-IPO, total annual gross revenues of $1.235 billion or more, or issuance of more than $1.0 billion in non-convertible debt[172]. - The company has reduced disclosure obligations regarding executive compensation as a smaller reporting company[173]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[175]. - The company may present only two years of audited financial statements and related Management's Discussion and Analysis under EGC provisions[171].